Elecsys probnp immunoassay

Manufactured by Roche

Sourced in Switzerland

The Elecsys proBNP Immunoassay is a laboratory diagnostic test developed by Roche. It is designed to quantitatively measure proBNP (pro-brain natriuretic peptide) levels in human blood samples. The test utilizes electrochemiluminescence technology to detect and quantify proBNP concentrations.

Automatically generated - may contain errors

Lab products found in correlation

Elecsys 2010 platform, by Roche (1 mentions) Au5800 automatic biochemical analyzer, by Beckman Coulter (1 mentions) Cobas e601, by Roche (1 mentions)

Spelling variants of this product

Elecsys immunoassay (43 citations) Elecsys proBNP (31 citations) Elecsys NT-proBNP immunoassay (7 citations) Elecsys proBNP II immunoassay (2 citations) Elecsys proBNP sandwich immunoassay (2 citations)

9 protocols using elecsys probnp immunoassay

Quantifying Serum NT-proBNP Levels

Check if the same lab product or an alternative is used in the 5 most similar protocols

At the screening examination, serum samples were collected and frozen at −80°C. In 2009 we thawed these serum samples to measure the NT‐proBNP levels. NT‐proBNP levels were quantified with a second‐generation commercial kit, the Elecsys proBNP Immunoassay,30 on an Elecsys 2010 platform (Roche Diagnostics, Risch, Switzerland). Serum NT‐proBNP levels were divided into 4 categories according to the current guidelines and prior reports: ≤54, 55 to 124, 125 to 299, and ≥300 pg/mL.15, 16, 31

Nagata T., Ohara T., Hata J., Sakata S., Furuta Y., Yoshida D., Honda T., Hirakawa Y., Ide T., Kanba S., Kitazono T., Tsutsui H, & Ninomiya T. (2019). NT‐proBNP and Risk of Dementia in a General Japanese Elderly Population: The Hisayama Study. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 8(17), e011652.

+ Open protocol

+ Expand

NT-proBNP Measurement in Serum and Urine

Check if the same lab product or an alternative is used in the 5 most similar protocols

At the screening examination, blood samples were collected from an antecubital vein. Urine samples were also collected at the time of the health checkup visit. A portion of each serum and urinary sample was stored at – 80 °C until the measurement of NT-proBNP concentrations in 2009 and 2018, respectively. Serum and urinary concentrations of NT-proBNP were determined using the Elecsys proBNP Immunoassay (Elecsys 2010 from Roche Diagnostics, Switzerland) [26 (link)]. The assay limit of detection was 5 pg/mL. For 20 subjects whose serum NT-proBNP concentrations were lower than the assay limit, the serum concentrations were defined as 5 pg/mL for statistical analyses. No subjects had urinary NT-proBNP concentrations lower than the assay limit.

Yamasaki K., Hata J., Ide T., Nagata T., Sakata S., Yoshida D., Honda T., Hirakawa Y., Nakano T., Kitazono T., Tsutsui H, & Ninomiya T. (2021). Urinary N-terminal pro–B-type natriuretic peptide as a biomarker for cardiovascular events in a general Japanese population: the Hisayama Study. Environmental Health and Preventive Medicine, 26, 47.

+ Open protocol

+ Expand

Comprehensive Cohort Assessment Protocol

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Standardized questionnaires, physical examination and laboratory measurements at baseline and follow-up provided information on covariates of interest. Medication use was determined from an inventory. These procedures have been described previously.(Bild et al., 2002 (link)) Covariates of interest included socio-demographic factors (age, sex, race/ethnicity, education status), lifestyle factors (physical activity assessed as intentional moderate/vigorous exercise in METS*min/week, and smoking status) and body size (height and weight measured using standardized procedures). Blood pressure (resting) was measured using a Dinamap automated sphygmomanometer in the seated position with the average of the 2nd and 3rd readings used. Diabetes was assessed by self-reported physician diagnosis, fasting glucose level ≥126 mg/dL, or use of hypoglycaemic medication. N-terminal pro-B type NP (NT-proBNP) was measured at visit 1 using Elecsys proBNP immunoassay from Roche Diagnostics Corporation (Indianapolis, IN) at the University of California San Diego.(Ying et al., 2018 (link), Choi et al., 2012 (link))

Subramanya V., Zhao D., Ouyang P., Ying W., Vaidya D., Ndumele C.E., Lima J.A., Guallar E., Hoogeveen R.C., Shah S.J., Heckbert S.R., Kass D.A., Post W.S, & Michos E.D. (2021). Cyclic Guanosine Monophosphate and 10-Year Change in Left Ventricular Mass: the Multi-Ethnic Study of Atherosclerosis (MESA). Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, 26(4), 309-317.

+ Open protocol

+ Expand

Biomarkers in Heart Failure Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols

Plasma and serum were obtained for biomarker determination at baseline, 12, and 36 weeks after randomization. The baseline measurements were made at randomization after a placebo run-in phase. Measurements after randomization to valsartan or LCZ696 were made in 12 and 36 weeks. NT-proBNP and matrix metalloproteinase-2 (MMP-2) were measured in plasma and collagen III N-terminal propeptide (PIIINP) was measured in serum at Quest Diagnostics (Valencia, CA) using the Elecsys proBNP immunoassay (Roche Diagnostics, Indianapolis, IN), the Quantikine MMP-2 immunoassay (R and D Systems, Minneapolis, MN), and the UniQ PIIINP radioimmunoassay (Orion Diagnostics, Espoo, Finland). The soluble form of ST-2 (sST-2, an interleukin-1 receptor family member) was measured in serum at Critical Diagnostics (San Diego, CA) using their Presage immunoassay, and Galectin 3 (Gal-3) was measured in serum at Clinical Reference Laboratories (Lenexa, KS) using an enzyme-linked immunosorbent assay (BG Medicine, Waltham, MA).

Zile M.R., Jhund P.S., Baicu C.F., Claggett B.L., Pieske B., Voors A.A., Prescott M.F., Shi V., Lefkowitz M., McMurray J.J, & Solomon S.D. (2016). Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. Circulation. Heart failure, 9(1), e002551.

+ Open protocol

+ Expand

Blood Sample Collection and Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

For all patients signed the informed consent, the blood was collected through the cubital vein and injected into the anticoagulant tubes and coagulant tubes with patients' limosis condition on the morning of the second day after admission. All serological tests were completed by the laboratory division of our hospital using AU 5800 automatic biochemical analyzer (Beckman Coulter, USA) and an automatic analyzer for NT-proBNP (Roche Elecsys®proBNP immunoassay, Switzerland). The unit of NT-proBNP is pg/mL and the unit of GFR is ml/(min·1.73 m²).

Wang K., Ni G., Wu Q., Zhou Y., Yao W., Zhang H, & Li X. (2020). Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide and Glomerular Filtration Rate in Patients With Acute Heart Failure. Frontiers in Cardiovascular Medicine, 7, 123.

+ Open protocol

+ Expand

Serum NT-proBNP Levels and Classification

Check if the same lab product or an alternative is used in the 5 most similar protocols

Frozen serum samples were collected at the baseline survey, and these were thawed in 2009 to measure serum NT-proBNP concentrations. Therefore, only baseline data of serum NT-proBNP were available. Serum NT-proBNP levels were measured by the Elecsys proBNP Immunoassay (Roche Diagnostics, Risch, Switzerland) in 2009.²⁷ (link) Participants were divided into 4 groups based on their serum NT-proBNP levels, i.e., serum NT-proBNP<55, 55–124, 125–299, and ≥300 pg/ml, according to the guidelines of the American Heart Association and the European Society of Cardiology, and previous studies.⁶ (link)^,⁷ (link)^,⁹ (link)

Sasaki T., Oishi E., Nagata T., Sakata S., Chen S., Furuta Y., Honda T., Yoshida D., Hata J., Tsuboi N., Kitazono T., Yokoo T, & Ninomiya T. (2021). N-Terminal Pro–B-Type Natriuretic Peptide and Incident CKD. Kidney International Reports, 6(4), 976-985.

+ Open protocol

+ Expand

NT-proBNP Measurement Harmonization

Check if the same lab product or an alternative is used in the 5 most similar protocols

NT‐proBNP levels were primarily measured using the Elecsys proBNP immunoassay (Roche Diagnostics Corporation, Indianapolis, IN) at the University of California San Diego and the University of Vermont.18 Additional measurements were performed using the Cobas e601 (Roche Diagnostics Corporation, Indianapolis, IN) at the University of Maryland.21 There was harmonization of the NT‐proBNP assays across the different Roche platforms. The range of measurements was 5 to 35 000 pg/mL. The intra‐assay and interassay coefficients of variation, respectively, were 2.7% and 3.2% at 175 pg/mL, 2.4% and 2.9% at 35 pg/mL, 1.9% and 2.6% at 1068 pg/mL, and 1.8% and 2.3% at 4962 pg/mL.18

Ying W., Zhao D., Ouyang P., Subramanya V., Vaidya D., Ndumele C.E., Guallar E., Sharma K., Shah S.J., Kass D.A., Hoogeveen R.C., Lima J.A., Heckbert S.R., deFilippi C.R., Post W.S, & Michos E.D. (2019). Associations Between the Cyclic Guanosine Monophosphate Pathway and Cardiovascular Risk Factors: MESA. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 8(24), e013149.

+ Open protocol

+ Expand

Serum VEGF-C and NT-proBNP Measurement

Check if the same lab product or an alternative is used in the 5 most similar protocols

VEGF-C levels were measured in the serum samples. R&D Systems kit (Minneapolis, MN) (Catalog Number DVEC00) was used for the assays according to the user instructions. NT-proBNP was measured on the Elecsys 2010 analyzer (Elecsys proBNP Immunoassay; Roche Diagnostics).

Sevinc M., Hasbal N.B., Basturk T., Ozcafer P.N., Kocas B.B., Kilickesmez K., Ozel A., Sakaci T., Ahbap E., Unsal A, & Koc Y. (2021). Comparison of lung ultrasound and other volumetric methods in peritoneal dialysis patients. Medicine, 100(3), e23856.

+ Open protocol

+ Expand

Serum NT-proBNP Measurement Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

At baseline, blood samples were collected from an antecubital vein, and a portion of the serum was stored at -80 °C until use for the measurement of serum NT-proBNP levels in 2009. Serum NT-proBNP levels were measured using an Elecsys proBNP Immunoassay (Roche Diagnostics, Risch, Switzerland). Serum NT-proBNP levels were divided into four categories: ≤ 54, 55-124, 125-299, and ≥ 300 pg/mL, according to the current guidelines and prior reports [6] (link)[7] (link)[8] (link)11, (link)27] (link).

Nagata T., Hata J., Sakata S., Oishi E., Honda T., Furuta Y., Ohara T., Yoshida D., Hirakawa Y., Shibata M., Ide T., Kitazono T., Tsutsui H, & Ninomiya T. (2020). Serum N-terminal pro-B-type natriuretic peptide as a predictor for future development of atrial fibrillation in a general population: the Hisayama Study. International journal of cardiology, 320.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!